Lumida
/ISRG
⌘K
Intuitive Surgical Inc

Intuitive Surgical Inc

ISRG
$345.42USD-14.15%-56.91 today

MARKET CAP

122.3B

P/E (TTM)

33.8x

FWD P/E

30.9x

DAY RANGE

$345 – $368

52W RANGE

$345
$604

AI Summary

Stalk
StalkMedium

ISRG sits in a Stage 4 decline but is mean-reversion eligible after a Post-Capitulation cluster signals selling exhaustion. Short-term structure remains below declining EMAs and ST trend is down, so execution is deferred. We will stalk for a pullback into the defended demand zone or rising EMA region before initiating a long.

  • Q1 2026 revenue of $2.77 B (+23% YoY) with total procedures +17%.
  • Recurring revenue makes up 86%, supporting stable cash flows.
  • Elective procedures and tender activity remain subdued, slowing growth.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Intuitive Surgical, Inc. (NASDAQ: ISRG) is a leading pioneer in robotic-assisted surgical systems, most notably known for its da Vinci Surgical System. The company specializes in promoting minimally invasive surgical procedures across various medical specialties, significantly enhancing surgical precision and patient outcomes. Intuitive Surgical's strategic focus on advancing technology and expanding its global presence positions it prominently within the growing trends of robotic-assisted surgery and minimally invasive treatment modalities.

Bull says

  • Q1 2026 revenue of $2.77 B (+23% YoY) with total procedures +17%.
  • Recurring revenue makes up 86%, supporting stable cash flows.
  • Operating margin at 39% and EPS $2.50 beat estimates.
  • Da Vinci 5 system and ION platform drive next-gen innovation.
  • $1.1 B share buyback approved, underscoring shareholder return focus.
  • High profitability and growth factor exposures support strength.

Bear says

  • Elective procedures and tender activity remain subdued, slowing growth.
  • Regulatory changes in China and Japan constrain capital approvals.
  • Elevated leverage risk may pressure financials if volumes fall.
  • Stretched valuation metrics risk future cash‐flow underperformance.
  • Intensifying competition erodes pricing power in key markets.
  • Weak price momentum signals investor caution on ISRG stock.

Investment themes with ISRG

Robotics +0.45%

Robotics and automation technology companies

IPGP · ZBRA · 6954.T
Medical Devices +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 07-17-2026neutral

Transcript signals

Read full transcript analysis ›